Vertex Pharmaceuticals Incorporated logo

Vertex Pharmaceuticals Incorporated (VRTX)

Market Closed
7 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS)
$
505. 56
+3.25
+0.647%
$
133.69B Market Cap
30.83 P/E Ratio
- Div Yield
458,870 Volume
14.94 Eps
$ 502.31
Previous Close
Add Transaction
Day Range
503.94 511.5
Year Range
400.86 560.25
Want to track VRTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Here's Why Vertex Pharmaceuticals (VRTX) Gained But Lagged the Market Today

Here's Why Vertex Pharmaceuticals (VRTX) Gained But Lagged the Market Today

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $495.91, indicating a +0.88% shift from the previous trading day.

Zacks | 2 years ago
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider

Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $490.85, signifying a +0.43% move from its prior day's close.

Zacks | 2 years ago
Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).

Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).

Vertex has built an empire from cystic fibrosis treatment, generating billions of dollars in annual revenue. The company is set to dominate the market through the late 2030s -- and possibly beyond.

Fool | 2 years ago
1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever

1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever

Vertex Pharmaceuticals has significantly outpaced the market in the past few decades. The company owes its performance to a well-defined strategy and its innovative abilities.

Fool | 2 years ago
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA

Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA

The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.

Zacks | 2 years ago
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 2 years ago
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note

Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $474.95, signifying a +1.33% move from its prior day's close.

Zacks | 2 years ago
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock

Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 2 years ago
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead

Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead

This magnificent drugmaker is much smaller than Eli Lilly, but is still large and successful. It has massive growth opportunities in multiple markets.

Fool | 2 years ago
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts

Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $467.28, indicating a -1.35% shift from the previous trading day.

Zacks | 2 years ago
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors

Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $475.79, signifying a -1.19% move from its prior day's close.

Zacks | 2 years ago
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Zacks | 2 years ago
Loading...
Load More